Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

Even with the CVS formulary change (moving away from Zepbound) putting ~200,000 patients at risk, says the analyst, Eli Lilly's market share — currently around 70-75% of new patients — and ...

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

CVS Health opts for Wegovy and Saxenda on its formulary; Zepbound excluded. Millions affected as coverage choices impact cost and access to obesity drugs.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of insurance-imposed limits that disrupt treatment.

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.